Martin Sanabria

Deputy Director Hematology
Bayer, Basel, Switzerland
Basel, Basel-Stadt, Switzerland

Presentation(s):

• PB1263 - Third Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol in Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World HEM-POWR Study

  Tuesday, June 27, 2023
  18:30 – 19:30 ET